Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Paricalcitol in Hemodialysis Patients with SHPT
NCT00701805Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2008
- Primary completion
- Dec 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of paricalcitol in secondary hyperparathyroidism (SHPT) (4 arms), sponsored by Abbott Laboratories. Primary endpoints: Percentage of Participants With Hypercalcemia at Week 53 and Percentage of Participants With Hyperphosphatemia at Week 53. Started Jul 2008; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00701805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701805.